46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05247216 (ClinicalTrials.gov) | March 26, 2021 | 31/5/2021 | A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis | A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Hemay007 800 mg QD group;Drug: Hemay007 1200 mg QD group;Drug: Hemay007 600 mg QD group;Drug: Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co.,Ltd | NULL | Recruiting | 18 Years | 75 Years | All | 140 | Phase 2 | China |